Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 397

1.

Retraction.

[No authors listed]

Blood Res. 2018 Jun;53(2):182. doi: 10.5045/br.2018.53.2.182. Epub 2018 Jun 25.

2.

Granulocytic dysplasia: an indicator of clonal evolution in patients with chronic myeloid leukemia.

Rajpal S, Nampoothiri RV, Sreedharanunni S, Parihar M, Malhotra P, Varma N.

Blood Res. 2018 Jun;53(2):180-181. doi: 10.5045/br.2018.53.2.180. Epub 2018 Jun 25. No abstract available.

3.

Acetate moderately attenuates the generation of neutrophil extracellular traps.

Ohbuchi A, Kono M, Takenokuchi M, Imoto S, Saigo K.

Blood Res. 2018 Jun;53(2):177-180. doi: 10.5045/br.2018.53.2.177. Epub 2018 Jun 25. No abstract available.

4.

Primary CNS lymphoma: latest updates and a 10-year monocenter experience.

Cencini E, Fabbri A, Schiattone L, Cerase A, Bocchia M.

Blood Res. 2018 Jun;53(2):174-177. doi: 10.5045/br.2018.53.2.174. Epub 2018 Jun 25. No abstract available.

5.

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia.

Kavanagh S, Bril V, Lipton JH.

Blood Res. 2018 Jun;53(2):172-174. doi: 10.5045/br.2018.53.2.172. Epub 2018 Jun 25. No abstract available.

6.

Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA).

Jain P, Konoplev S, Benjamini O, Romagura J, Burger JA.

Blood Res. 2018 Jun;53(2):169-172. doi: 10.5045/br.2018.53.2.169. Epub 2018 Jun 25. No abstract available.

7.

Microangiopathic hemolytic anemia as initial presentation of recurrent colon cancer.

Park J.

Blood Res. 2018 Jun;53(2):167-169. doi: 10.5045/br.2018.53.2.167. Epub 2018 Jun 25. No abstract available.

8.

Evaluation of thrombocytopenia in the hematology clinic: a case series from a large tertiary care center.

Ravindran A, Go RS, Reichard KK, Marshall AL.

Blood Res. 2018 Jun;53(2):166-167. doi: 10.5045/br.2018.53.2.166. Epub 2018 Jun 25. No abstract available.

9.

The first concurrent diagnosis of acute symptomatic Babesiosis and chronic myeloid leukemia in a healthy young adult.

Xie Y, Visconte V, Duan L, Rogers HJ.

Blood Res. 2018 Jun;53(2):163-166. doi: 10.5045/br.2018.53.2.163. Epub 2018 Jun 25. No abstract available.

10.

Synchronous hairy cell leukemia and chronic lymphocytic leukemia: a case report with a brief review of literature.

Rastogi P, Jeyaraman P, Sachdeva MU, Malhotra P, Ahluwalia J.

Blood Res. 2018 Jun;53(2):160-163. doi: 10.5045/br.2018.53.2.160. Epub 2018 Jun 25. No abstract available.

11.

The incidence of atypical patterns of BCR-ABL1 rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML).

Švabek ŽT, Josipović M, Horvat I, Zadro R, Davidović-Mrsić S.

Blood Res. 2018 Jun;53(2):152-159. doi: 10.5045/br.2018.53.2.152. Epub 2018 Jun 25.

12.

Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin.

Park BK, Kim HS, Kim S, Lee JW, Park YS, Jang PS, Chung NG, Jeong DC, Cho B.

Blood Res. 2018 Jun;53(2):145-151. doi: 10.5045/br.2018.53.2.145. Epub 2018 Jun 25.

13.

Leukemia propagating cells in Philadelphia chromosome-positive ALL: a resistant phenotype with an adverse prognosis.

El-Menshawy N, Abd-Aziz SM, Elkhamisy EM, Ebrahim MA.

Blood Res. 2018 Jun;53(2):138-144. doi: 10.5045/br.2018.53.2.138. Epub 2018 Jun 25.

14.

Clinical characteristics and outcomes of thrombotic microangiopathy in Malaysia.

Yap YY, Sathar J, Law KB, Zulkurnain PAB, Edmund SC, Chang KM, Baker R.

Blood Res. 2018 Jun;53(2):130-137. doi: 10.5045/br.2018.53.2.130. Epub 2018 Jun 25.

15.

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents.

Lee SE, Jeon YW, Yoon JH, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG, Kim DW, Lee JW, Min WS, Min CK.

Blood Res. 2018 Jun;53(2):123-129. doi: 10.5045/br.2018.53.2.123. Epub 2018 Jun 25.

16.

Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent.

Sekiguchi N, Hamano A, Kitagawa T, Kurihara Y, Ito K, Kurimoto M, Watanabe K, Hirano K, Noto S, Yamada K, Takezako N.

Blood Res. 2018 Jun;53(2):117-122. doi: 10.5045/br.2018.53.2.117. Epub 2018 Jun 25.

17.

Clinical characteristics and treatment courses for cytomegalovirus-associated thrombocytopenia in immunocompetent children after neonatal period.

Jin MJ, Kim Y, Choi EM, Shim YJ, Kim HS, Suh JK, Kim JY, Lee KS, Park SY, Lee JM, Hah JO.

Blood Res. 2018 Jun;53(2):110-116. doi: 10.5045/br.2018.53.2.110. Epub 2018 Jun 25.

18.

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma.

Byun JM, Lee J, Shin SJ, Kang M, Yoon SS, Koh Y.

Blood Res. 2018 Jun;53(2):105-109. doi: 10.5045/br.2018.53.2.105. Epub 2018 Jun 25.

19.

Del(5q) myelodysplastic syndrome combined with pure red cell aplasia.

Park J.

Blood Res. 2018 Jun;53(2):104. doi: 10.5045/br.2018.53.2.104. Epub 2018 Jun 25. No abstract available.

20.

Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation.

Mandal T, Verma A, Talreja V, Parthiban SK, Gokarn A, Jain H, Bagal B, Tandon S, Sengar M, Shet T.

Blood Res. 2018 Jun;53(2):103. doi: 10.5045/br.2018.53.2.103. Epub 2018 Jun 25. No abstract available.

Supplemental Content

Loading ...
Support Center